Our Services
Medical Information
Helpful Resources
Published on: 9/14/2026
Diarrhea from Wegovy (semaglutide) is a common early side effect that usually lasts a few days to a couple of weeks as your body adjusts, and it often fades or improves after each dose increase settles. Most people find symptoms ease within 2 to 4 weeks of starting or escalating a dose, though some experience loose stools on and off for longer while at higher doses. Duration varies based on your dose, how quickly it was increased, other medications, and what you eat and drink, so there are several important factors to consider. Warning signs like diarrhea lasting more than two weeks, dehydration, severe stomach pain, fever, or blood in stool mean you should contact a clinician rather than wait it out; see below for the full timeline, self-care steps, and red flags.
If you are unsure whether your symptoms are normal adjustment or something that needs attention, a free, instant, online symptom check can help you sort out likely causes, spot urgent signs, and understand which next steps and questions to bring to your doctor.
Last reviewed for medical accuracy: 09/14/2026
How Long Does Wegovy Diarrhea Last Before It Goes Away on Its Own?
Wegovy® (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management. Gastrointestinal side effects are common, and diarrhea is one of them. Understanding why Wegovy causes diarrhea and how long it typically lasts can help you manage expectations and comfort while your body adjusts.
Diarrhea with Wegovy is usually related to its mechanism of action and the way your gastrointestinal (GI) system adapts during dose escalation. Key factors include:
Clinical trials and prescribing information indicate that most GI side effects are transient. Here’s what research and real-world experience tell us:
Most cases of Wegovy-related diarrhea are mild to moderate. You can often manage symptoms at home with simple strategies:
Stay Hydrated
Adjust Your Diet
Smaller, More Frequent Meals
Over-the-Counter Aids
Slow Dose Escalation (When Possible)
Monitor for Red Flags
While most episodes are self-limiting, contact your healthcare provider if you experience:
For a quick check of your symptoms, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you decide if you need to seek in-person care.
Wegovy has demonstrated substantial benefits in weight reduction and improvement of cardiovascular risk factors. GI side effects like diarrhea are common but usually mild and short-lived. Here’s how to stay on track:
By understanding why Wegovy causes diarrhea and what to expect in terms of duration, you can better navigate treatment and minimize discomfort. If you ever feel unsure or your symptoms escalate, don’t hesitate to reach out to your healthcare provider.
(References)
* Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017 Apr;5(4):251-260. doi: 10.1016/S2213-8587(17)30013-X. Epub 2017 Jan 17. PMID: 28110911.
* Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10. PMID: 33567185.
* Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K, SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647.
* Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022 Sep 1;21(1):169. doi: 10.1186/s12933-022-01604-7. Epub 2022 Sep 1. PMID: 36050763; PMCID: PMC9438179.
* Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjær MS, Krarup N, Lawitz E, Ratziu V, Sanyal AJ, Schattenberg JM, Newsome PN, NN9931-4492 investigators. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023 Jun;8(6):511-522. doi: 10.1016/S2468-1253(23)00068-7. Epub 2023 Mar 16. PMID: 36934740; PMCID: PMC10792518.
* France NL, Syed YY. Tirzepatide: A Review in Type 2 Diabetes. Drugs. 2024 Feb;84(2):227-238. doi: 10.1007/s40265-023-01992-4. Epub 2024 Feb 23. PMID: 38388874.
* Feier CVI, Vonica RC, Faur AM, Streinu DR, Muntean C. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review. Int J Mol Sci. 2024 Apr 15;25(8). doi: 10.3390/ijms25084346. Epub 2024 Apr 15. PMID: 38673931; PMCID: PMC11050669.
* Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA. 2024 Aug 20;332(7):571-584. doi: 10.1001/jama.2024.10816. PMID: 39037780.
* Moiz A, Filion KB, Toutounchi H, Tsoukas MA, Yu OHY, Peters TM, Eisenberg MJ. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Ann Intern Med. 2025 Feb;178(2):199-217. doi: 10.7326/ANNALS-24-01590. Epub 2025 Jan 7. PMID: 39761578.
* Garvey WT, Blüher M, Osorto Contreras CK, Davies MJ, Winning Lehmann E, Pietiläinen KH, Rubino D, Sbraccia P, Wadden T, Zeuthen N, Wilding JPH, REDEFINE 1 Study Group. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025 Aug 14;393(7):635-647. doi: 10.1056/NEJMoa2502081. Epub 2025 Jun 22. PMID: 40544433.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.